Cargando…
Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial
BACKGROUND: Prader-Willi syndrome (PWS) is a rare complex genetic disorder and is characterized by short stature, muscular hypotonia, abnormal body composition, psychomotor retardation, and hyperphagia. Recombinant human growth hormone (rhGH) treatment improves the symptoms in children with PWS, and...
Autores principales: | Yang, Aram, Choi, Jin-Ho, Sohn, Young Bae, Eom, Yunae, Lee, Jiyoon, Yoo, Han-Wook, Jin, Dong-Kyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739953/ https://www.ncbi.nlm.nih.gov/pubmed/31511031 http://dx.doi.org/10.1186/s13023-019-1195-1 |
Ejemplares similares
-
Response to low dose growth hormone treatment in infants and toddlers with Prader-Willi Syndrome
por: Scheermeyer, Elly, et al.
Publicado: (2015) -
Prader-Willi Syndrome and Growth Hormone Deficiency
por: Aycan, Zehra, et al.
Publicado: (2014) -
Growth Hormone Therapy in Adults with Prader-Willi Syndrome
por: Vogt, Karen S., et al.
Publicado: (2015) -
Growth hormone therapy for Prader–willi syndrome: challenges and solutions
por: Grugni, Graziano, et al.
Publicado: (2016) -
Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome
por: Deal, Cheri L., et al.
Publicado: (2013)